Advertisement

 

 

Timing of Systemic Chemotherapy in Patients With Colorectal Peritoneal Carcinomatosis Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Timing of Systemic Chemotherapy in Patients With Colorectal Peritoneal Carcinomatosis Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Author Information (click to view)

van Eden WJ, Kok NF, Jóźwiak K, Lahaye ML, Beets GL, van Leerdam ME, Boot H, Aalbers AG,


van Eden WJ, Kok NF, Jóźwiak K, Lahaye ML, Beets GL, van Leerdam ME, Boot H, Aalbers AG, (click to view)

van Eden WJ, Kok NF, Jóźwiak K, Lahaye ML, Beets GL, van Leerdam ME, Boot H, Aalbers AG,

Advertisement

Diseases of the colon and rectum 60(5) 477-487 doi 10.1097/DCR.0000000000000774
Abstract
BACKGROUND
Timing of systemic chemotherapy in patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is controversial. Preoperative systemic chemotherapy may offer benefits.

OBJECTIVE
The purpose of this study was to evaluate the effect of timing of systemic chemotherapy on survival.

DESIGN
This was a retrospective cohort study.

SETTINGS
The study was conducted at a tertiary referral center.

PATIENTS
Patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy from January 2004 until June 2015 were included.

MAIN OUTCOME MEASURES
The influence of patient-related, tumor-related, and treatment-related factors on survival were investigated using Cox regression models. Main outcome was overall survival.

RESULTS
A total of 280 consecutive patients underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. In group A, 78 patients (28%) were treated with preoperative or perioperative chemotherapy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy. In group B, 169 patients (60%) were intentionally treated with cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, and adjuvant chemotherapy. In group C, 33 patients (12%) had received their chemotherapy before peritoneal carcinomatosis was diagnosed. Median overall survival was 36.9 months (interquartile range, 20.6-79.7 mo) in group A, 43.1 months (interquartile range, 25.7-95.9 mo) in group B, and 34.0 months (interquartile range, 20.0-53.7 mo) in group C (p = 0.19). The extent of peritoneal carcinomatosis (region count of 3-5, HR = 1.58 (95% CI, 1.02-2.45), and 6-7, HR = 3.34 (95% CI, 1.66-6.72) vs 1-2 regions), a higher lymph node ratio (HR = 7.96 (95% CI, 2.16-29.31)), and cycles of systemic chemotherapy (0 cycles, HR = 2.52 (95% CI, 1.48-4.29)) and partial chemotherapy (HR = 2.15 (95% CI, 1.27-3.65) vs complete chemotherapy) were associated with poorer overall survival.

LIMITATIONS
Selection bias is present because of the retrospective design of this study.

CONCLUSIONS
Timing of systemic chemotherapy does not appear to have impact on survival in patients with colorectal peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Submit a Comment

Your email address will not be published. Required fields are marked *

1 × 1 =

[ HIDE/SHOW ]